Ocular Therapeutix Releases Q2 2026 Financial Results
Ocular Therapeutix, Inc. reported a net loss of $78.8 million in Q2 2026, though its per-share loss narrowed to -$0.35 from -$0.39 year-over-year. The biopharmaceutical company generated $13.5 million in revenue, a slight increase of 0.1% from Q2 2025, primarily from DEXTENZA product sales. …